Amgen sees ‘strategic fit’ for $13.4bn Otezla 27-Aug-2019 By Ben Hargreaves Amgen confirms that it will acquire blockbuster psoriasis treatment Otezla, freeing BMS and Celgene to complete their merger deal by the end of 2019.
BMS has to divest blockbuster to complete Celgene acquisition 25-Jun-2019 By Ben Hargreaves The share price of BMS sank by over 7% after it stated that it would need to divest Celgene’s Otezla, a blockbuster treatment for psoriasis and psoriatic arthritis.